A recent study conducted by Dr. med. Michael Winkelmann and his colleagues at the LMU Klinikum München explored the association between TGR dynamics from pre-treatment to post-treatment imaging and the patients' outcomes.
The research provides valuable insights into the potential of TGR as a novel prognostic imaging biomarker in the context of CAR-T therapy for patients with relapsed or refractory non-Hodgkin's lymphoma.
Study with mint Lesion™ Uncovers the Impact of Tumor Growth Rate in Predicting the Efficacy of CAR-T-cell Therapy in Lymphoma Patients
Related Resources
Related Resources
Leave No Data Behind: Commitment to Data Excellence
At Mint Medical, we understand data as a cornerstone for improving patient care and groundbreaking research. Our mission is clear: Leave No Data…
ESOI-EORTC Workshop: Hands-On Training in Assessing Tumor Response to Treatment
The ESOI-EORTC workshop, hosted by the European Society of Oncological Imaging (ESOI) and the European Organization for Research and Treatment of…
Systems on FHIR: Driving Healthcare Innovation Through Interoperability
Interoperability is revolutionizing healthcare by enabling the seamless exchange of patient data across systems. This efficient data flow is critical…